利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.026 秒)

    DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO
    1.
    发明申请
    DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO 有权
    检测和定量生物体内的生物体形成

    公开(公告)号：US20100111861A1

    公开(公告)日：2010-05-06

    申请号：US12610871

    申请日：2009-11-02

    申请人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    发明人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    IPC分类号： A61K51/04

    CPC分类号： A61K51/0406 ,  A61K49/0008 ,  G01N33/5011

    摘要： A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.

    摘要翻译： 测量抗癌剂在产生受试者的癌细胞的DNA中的脱碱性（AP）位点的功效的方法包括向受试者施用在至少一种癌细胞中产生AP位点的抗癌剂和AP内切核酸酶抑制剂探针。 AP内切核酸酶抑制剂探针包括用于检测受试者中的探针的检测部分。 然后测量与受试者的癌细胞结合的探针的量。 与受试者的癌细胞结合的探针的量指示抗癌剂在产生受试者的癌细胞中的AP位点的功效。

    Detection and quantification of abasic site formation in vivo
    7.
    发明授权
    Detection and quantification of abasic site formation in vivo 有权
    体内无碱基位点形成的检测和定量

    公开(公告)号：US08367332B2

    公开(公告)日：2013-02-05

    申请号：US12610871

    申请日：2009-11-02

    申请人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    发明人： Lili Liu ,  Yanming Wang ,  Stanton Gerson

    IPC分类号： C12Q1/68 ,  C07H21/00

    CPC分类号： A61K51/0406 ,  A61K49/0008 ,  G01N33/5011

    摘要： A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.

    摘要翻译： 测量抗癌剂在产生受试者的癌细胞的DNA中的脱碱性（AP）位点的功效的方法包括向受试者施用在至少一种癌细胞中产生AP位点的抗癌剂和AP内切核酸酶抑制剂探针。 AP内切核酸酶抑制剂探针包括用于检测受试者中的探针的检测部分。 然后测量与受试者的癌细胞结合的探针的量。 与受试者的癌细胞结合的探针的量指示抗癌剂在产生受试者的癌细胞中的AP位点的功效。

    Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs
    9.
    发明申请
    Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs 审中-公开
    与药物不良血液反应相关的HLA-C基因的遗传标记

    公开(公告)号：US20060183146A1

    公开(公告)日：2006-08-17

    申请号：US11351601

    申请日：2006-02-10

    申请人： Maria Athanasiou ,  Stanton Gerson

    发明人： Maria Athanasiou ,  Stanton Gerson

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： Genetic markers in the HLA-C gene associated with adverse hematological response to drug therapy are disclosed. Compositions and methods for detecting and using these HLA-C markers in a variety of clinical applications are disclosed. Such applications include methods for testing an individual for susceptibility for an adverse hematological response, methods of selecting the appropriate drug therapy for patients based on the presence or absence of a HLA-C marker, and products comprising a drug with hematological toxicity that are approved for treating patients lacking a genetic marker.

    摘要翻译： 公开了与药物治疗的不良血液反应相关的HLA-C基因中的遗传标记。 公开了用于在各种临床应用中检测和使用这些HLA-C标志物的组合物和方法。 这样的应用包括用于测试个体对不利血液反应的易感性的方法，基于HLA-C标志物的存在或不存在为患者选择合适的药物疗法的方法，以及包含具有血清学毒性的药物的产品，其被批准用于 治疗缺乏遗传标记的患者。

    Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
    10.
    发明申请
    Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs 审中-公开
    HLA-DQBI基因中的遗传标记与药物的不良血液反应相关

    公开(公告)号：US20060177860A1

    公开(公告)日：2006-08-10

    申请号：US11351394

    申请日：2006-02-09

    申请人： Maria Athanasiou ,  Stanton Gerson

    发明人： Maria Athanasiou ,  Stanton Gerson

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： Genetic markers in the HLA-DQB1 gene associated with adverse hematological response to drug therapy are disclosed. Compositions and methods for detecting and using these HLA-DQB1 markers in a variety of clinical applications are disclosed. Such applications include methods for testing an individual for susceptibility for an adverse hematological response, methods of selecting the appropriate drug therapy for patients based on the presence or absence of a HLA-DQB1 marker, and products comprising a drug with hematological toxicity that are approved for treating patients lacking a genetic marker.

    摘要翻译： 公开了与药物治疗的不良血液反应相关的HLA-DQB1基因中的遗传标记。 公开了在各种临床应用中检测和使用这些HLA-DQB1标志物的组合物和方法。 这样的应用包括用于测试个体对不利血液反应的易感性的方法，基于HLA-DQB1标志物的存在或不存在为患者选择适当的药物疗法的方法，以及包含经批准用于 治疗缺乏遗传标记的患者。